<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Challenges in modern medicine</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.52575/2687-0940-2025-48-4-468-483</article-id><article-id pub-id-type="publisher-id">265</article-id><article-categories><subj-group subj-group-type="heading"><subject>CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Secondary Arterial Hypertension in Patients with a Neuroendocrine Tumor of the Adrenal Glands&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Secondary Arterial Hypertension in Patients with a Neuroendocrine Tumor of the Adrenal Glands&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Khorolets</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="en"><surname>Khorolets</surname><given-names>Ekaterina V.</given-names></name></name-alternatives><email>kata_maran@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Shaposhnikova</surname><given-names>Sofia S.</given-names></name><name xml:lang="en"><surname>Shaposhnikova</surname><given-names>Sofia S.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Otrutsky</surname><given-names>Sergey S.</given-names></name><name xml:lang="en"><surname>Otrutsky</surname><given-names>Sergey S.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Parshikov</surname><given-names>Evgeny G.</given-names></name><name xml:lang="en"><surname>Parshikov</surname><given-names>Evgeny G.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2025</year></pub-date><volume>48</volume><issue>4</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2025/4/АПМ_2025_Том_48__4_468-483.pdf" /><abstract xml:lang="ru"><p>The article aims to stress the importance of revealing the causes of arterial hypertension (AH) and providing differential diagnostics. Being a globally spread issue that is discussed by healthcare ptofessionals worldwide, hypertension may be described as a medical and social problem. Most clinical examples are accompanied with the presence of an essential form of hypertension, though 5&amp;ndash;25 % of cases are attributed specifically to the secondary (symptomatic) form of hypertension (SAH). This article discusses such a case in a young patient with pheochromocytoma. This clinical instance is an illustration of SAH development, which requires a competent study of the root cause, given the complexity of diagnosis at the initial stages of the disease, as well as the correct choice of patient management tactics.</p></abstract><trans-abstract xml:lang="en"><p>The article aims to stress the importance of revealing the causes of arterial hypertension (AH) and providing differential diagnostics. Being a globally spread issue that is discussed by healthcare ptofessionals worldwide, hypertension may be described as a medical and social problem. Most clinical examples are accompanied with the presence of an essential form of hypertension, though 5&amp;ndash;25 % of cases are attributed specifically to the secondary (symptomatic) form of hypertension (SAH). This article discusses such a case in a young patient with pheochromocytoma. This clinical instance is an illustration of SAH development, which requires a competent study of the root cause, given the complexity of diagnosis at the initial stages of the disease, as well as the correct choice of patient management tactics.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>symptomatic arterial hypertension</kwd><kwd>pheochromocytoma</kwd><kwd>neuroendocrine tumor of the adrenal glands</kwd><kwd>cateholamines</kwd><kwd>endocrine disorders</kwd></kwd-group><kwd-group xml:lang="en"><kwd>symptomatic arterial hypertension</kwd><kwd>pheochromocytoma</kwd><kwd>neuroendocrine tumor of the adrenal glands</kwd><kwd>cateholamines</kwd><kwd>endocrine disorders</kwd></kwd-group></article-meta></front><back><ack><p>Informed consent. The patient&amp;#39;s informed consent was obtained for the publication of data from his examination, survey, and clinical observation. All patient data was de-identified.</p></ack><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Aksenova A.V., Sivakova O.A., Blynova N.V., Danilov N.M., Elfimova E.M., Kislyak O.A., Litvin&amp;nbsp;A.Yu., Oshchepkova E.V., Fomin V.V., Chihladze N.M., Shchelkova G.V., Chazova I.E. 2021. The Consensus of Experts of the Russian Medical Society on Arterial Hypertension on the Diagnosis and Treatment of Resistant Arterial Hypertension. Therapeutic Archive. 93(9): 1018&amp;ndash;1029. doi: 10.26442/00403660.2021.09.201007</mixed-citation></ref><ref id="B2"><mixed-citation>Artamonova E.V., Beltsevich D.G., Bokhyan V.Yu., Geliashvili T.M., Gorbunova V.A., Delektorskaya V.V., Dolgushin M.B., Egorov A.V., Yemelyanova G.S., Zhukova L.G., Zhulikov Ya.A., Kasprzyk&amp;nbsp;S.M., Krylov A.S., Kuzminov A.E., Lyubimova N.V., Markovich A.A., Melnichenko&amp;nbsp;G.A., Orel N.F., Orlov&amp;nbsp;S.V., Orlova K.V., Orlova R.V., Pronin A.I., Romanov I.S., Trifanov V.S., Khomyakov V.M., Petrov L.O., Pirogov S.S., Fedenko A.A., Bolotina L.V., Falaleeva N.A., Filonenko E.V., 2025. Clinical Guidelines &amp;quot;Neuroendocrine Tumors&amp;quot;, Russian Association of Endocrinologists, Association of Oncologists of Russia, All-Russian Public Organization. Russian Society of Clinical Oncology. https://gastroscan.ru/literature/authors/15346</mixed-citation></ref><ref id="B3"><mixed-citation>Vaichulis I.A., Shaposhnik I.I. 2019. The Main Provisions of the International Recommendations for the Detection of Endocrine Hypertension. Cardiology. 59(10): 88&amp;ndash;96. doi: 10.18087/cardio.2019.10.2669</mixed-citation></ref><ref id="B4"><mixed-citation>Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash&amp;nbsp;O.L., Boytsov S.A., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva&amp;nbsp;E.N., Grinstein Yu.I., Drapkina O.M., Zhernakova Yu.V., Zvartau N.E., Irtyuga O.B., Kislyak&amp;nbsp;O.A., Koziolova N.A., Kosmacheva E.D., Kotovskaya Yu.V., Bobkova N.V., Libis R.A., Lopatin Yu.M., Nebiridze D.V., Nedoshivin A.O., Nikulina S.Yu., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Salasyuk A.S., Skibitsky V.V., Tkacheva O.N., Troitskaya E.A., Chazova I.E., Chesnikova&amp;nbsp;A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N. 2024. Clinical Guidelines. Arterial Hypertension in Adults. Russian Journal of Cardiology. 29(9): 6117. doi: 10.15829/1560-4071-2024-6117. EDN: GUEWLU</mixed-citation></ref><ref id="B5"><mixed-citation>Melnichenko G.A., Dedov I.I., Belaya Zh.E., Rozhinskaya L.Ya., Vagapova G.R., Volkova N.I., Grigor&amp;rsquo;ev&amp;nbsp;A.Yu., Grineva E.N., Marova E.I., Mkrtumayn A.M., Trunin Yu.Yu., Cherebillo V.Yu. 2015. Cushing&amp;rsquo;s Disease: The Clinical Features, Diagnostics, Differential Diagnostics, and Methods of Treatment. Problems of Endocrinology. 61(2): 55&amp;ndash;77. doi: 10.14341/probl201561255-77</mixed-citation></ref><ref id="B6"><mixed-citation>Muradian A.G., Kostin A.A., Vorobyov N.V., Tolkachev A.O. 2020. Metastatic Tumors of the Adrenal Gland. Epidemiology, Etiology, and Diagnosis. Oncology. P.A. Herzen Magazine. 9(3): 53&amp;ndash;60. doi: 10.17116/onkolog2020903153</mixed-citation></ref><ref id="B7"><mixed-citation>Chazova I.E., Chikhladze N.M., Blinova N.V., Belaya Zh.E., Danilov N.M., Elfimova E.M., Litvin A.Yu., Rozhinskaya L.Ya., Sviridenko N.Yu., Shvetsov M.Yu., Azizov V.A., Grigorenko E.A., Mitkovskaya&amp;nbsp;N.P., Mustafaev I.I., Polupanov A.G., Sarybaev A.Sh., Khamidullayeva G.A. 2023. Eurasian Clinical Guidelines for the Diagnosis and Treatment of Secondary (Symptomatic) Forms of Arterial Hypertension (2022). Eurasian Journal of Cardiology. (1): 6&amp;ndash;65. doi: 10.38109/2225-1685-2023-1-6-65</mixed-citation></ref><ref id="B8"><mixed-citation>Chikhladze N.M. 2020. Primary Hyperaldosteronism as a Possible Cause of the Resistant Course of Arterial Hypertension. Systemic Hypertension. 17(4): 20&amp;ndash;23. doi: 10.26442/ 2075082X.2020.4.200338</mixed-citation></ref><ref id="B9"><mixed-citation>Chikhladze N.M. Primary Hyperaldosteronism: Indications for Screening. 2022. Therapeutic Archive. 94(1): 107&amp;ndash;113. doi: 10.26442/00403660.202 2.01.201324</mixed-citation></ref><ref id="B10"><mixed-citation>Yukina M.Yu., Troshina E.A., Beltsevich D.G. 2015. Hereditary Syndromes Associated with Pheochromocytoma. Part 1. Therapeutic Archive. 87(9): 102&amp;ndash;105. doi: 10.17116/ terarkh2015879102-105</mixed-citation></ref><ref id="B11"><mixed-citation>Antonio K., Valdez M.M.N., Mercado-Asis L., Ta&amp;iuml;eb D., Pacak K. 2020. Pheochromocytoma/ paraganglioma: Recent Updates in Genetics, Biochemistry, Immunohistochemistry, Metabolomics, Imaging and Therapeutic Options. Gland Surg. 9(1): 105&amp;ndash;123. doi: 10.21037/gs.2019.10.25</mixed-citation></ref><ref id="B12"><mixed-citation>Aygun N., Uludag M. 2020. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 54: 159&amp;ndash;68. doi: 10.14744/SEMB.2020.18794</mixed-citation></ref><ref id="B13"><mixed-citation>Boot C.S. 2023. A Laboratory Medicine Perspective on the Investigation of Phaeochromocytoma and Paraganglioma. Diagnostics (Basel). 13: 2940. doi: 10.3390/diagnostics13182940</mixed-citation></ref><ref id="B14"><mixed-citation>Dogrul A.B., Cennet O., Dincer A.H. 2022. Minimally Invasive Techniques in Benign and Malignant Adrenal Tumors. World J Clin cases. 10(35): 12812&amp;ndash;12821. doi: 10.12998/wjcc.v10.i35.12812</mixed-citation></ref><ref id="B15"><mixed-citation>Ebbehoj A., Stochholm K., Jacobsen S.F. Trolle Ch., Jepsen P., Robaczyk M.G., Rasmussen A.K., Feldt-Rasmussen U., Thomsen R.W., S&amp;oslash;ndergaard E., Poulsen P.L. 2021. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. J. Clin. Endocrinol. Metab. 106(5): e2251-e2261. doi: 10.1210/clinem/dgaa965</mixed-citation></ref><ref id="B16"><mixed-citation>Garcia-Carbonero R., Matute Teresa F., Mercader-Cidoncha E., Mitjavila-Casanovas M., Robledo M., Tena&amp;nbsp;I., Alvarez-Escola C., Ar&amp;iacute;stegui M., Bella-Cueto M.R., Ferrer-Albiach C., Hanzu F.A. 2021. Multidisciplinary Practice Guidelines for the Diagnosis, Genetic Counseling and Treatment of Pheochromocytomas and Paragangliomas. Clin Transl Oncol. 23: 1995&amp;ndash;2019. doi: 10.1007/s12094-021-02622-9</mixed-citation></ref><ref id="B17"><mixed-citation>Lima J.V., Kater C.E. 2023. The Pheochromocytoma/Paraganglioma Syndrome: An Overview on Mechanisms, Diagnosis and Management. Int Braz J Urol. 49: 307&amp;ndash;19. doi: 10.1590/S1677-5538.IBJU.2023.0038</mixed-citation></ref><ref id="B18"><mixed-citation>Marcus C., Subramaniam R.M. 2023. Paragangliomas and Pheochromocytomas: Positron Emission Tomography/Computed Tomography Diagnosis and Therapy. PET Clin. 18: 233&amp;ndash;42. doi: 10.1016/j.cpet.2022.11.006</mixed-citation></ref><ref id="B19"><mixed-citation>Mete O., Asa S.L., Gill A.J., Kimura N., de Krijger R.R., Tischler A. 2022. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 33: 90&amp;ndash;114. doi: 10.1007/s12022-022-09704-6</mixed-citation></ref><ref id="B20"><mixed-citation>Mills K.T., Stefanescu A., He J. 2020. The Global Epidemiology of Hypertension. Nat Rev Nephrol. 16(4): 223&amp;ndash;37. doi: 10.1038/s41581-019-0244-2</mixed-citation></ref><ref id="B21"><mixed-citation>N&amp;ouml;lting S., Bechmann N., Taieb D., Beuschlein F., Fassnacht M., Kroiss M., Graeme Eisenhofer G., Grossman&amp;nbsp;A., Pacak K. 2022. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 43: 199&amp;ndash;239. doi: 10.1210/endrev/bnab019</mixed-citation></ref><ref id="B22"><mixed-citation>Passman J.E., Wachtel H. 2024. Management of Pheochromocytomas and Paragangliomas. Surg Clin North Am. 104:863&amp;ndash;81. doi: 10.1016/j.suc.2024.02.014</mixed-citation></ref><ref id="B23"><mixed-citation>Sarathy H., Salman L.A., Lee C., Cohen J.B. 2022. Evaluation and Management of Secondary Hypertension. Med Clin North Am. 106(2): 269&amp;ndash;83. doi: 10.1016/j.mcna.2021.11.004</mixed-citation></ref><ref id="B24"><mixed-citation>Schmiemann G., Gebhardt K., Hummers-Pradier E., Egidi G. 2012. Prevalence of Hyperaldosteronism in Primary Care Patients with Resistant Hypertension. J Am Board Fam Med. Jan-Feb; 25(1): 98&amp;ndash;103. doi: 10.3122/jabfm.2012.01.110099</mixed-citation></ref><ref id="B25"><mixed-citation>Sharma S., Fishbein L. 2023. Diagnosis and Management of Pheochromocytomas and Paragangliomas: A&amp;nbsp;Guide for the Clinician. Endocr Pract. 29: 999&amp;ndash;1006. doi: 10.1016/j.eprac.2023.07.027</mixed-citation></ref></ref-list></back></article>